

rs77283072 influences breast cancer susceptibility by regulating *CDKN2A* expression

GUANG-HUAN HE*, SHAO-DONG LIU*, XIAO-QIAN SHI, YING CHEN, LI SU, QIAO-NA SHI and CHANG SUN

College of Life Sciences, Shaanxi Normal University, Xi'an, Shaanxi 710119, P.R. China

Received July 7, 2022; Accepted November 25, 2022

DOI: 10.3892/ol.2023.13662

Abstract. Breast cancer is the cancer type with the highest morbidity rates in women, and previous genome-wide association studies (GWASs) have suggested that the single nucleotide polymorphism (SNP) rs1011970 is significantly associated with this disease. An analysis of data from the 1000 Genomes Project demonstrated that there is an SNP, rs77283072, in almost complete linkage disequilibrium with rs1011970, which should therefore present the same signal in a GWAS. However, the actual causal SNP and its associated underlying mechanism have yet to be elucidated. Therefore, the present study evaluated the role of rs77283072 in terms of its association with breast cancer. A dual-luciferase assay was performed, which demonstrated that the two alleles of rs1011970 did not exhibit significantly different reporter gene activity. However, the A allele of rs77283072 exhibited a significant increase in relative luciferase activity compared with the G allele, which suggested that rs77283072 was the causal SNP for breast cancer. Chromosome conformation capture demonstrated that the enhancer containing rs77283072 interacted with the promoter of cyclin-dependent kinase inhibitor 2A (*CDKN2A*). Furthermore, expression quantitative trait locus analysis demonstrated that the expression of *CDKN2A* was dependent on the genotype of rs77283072. Taken together, the findings of the present study provided novel insights into the mechanism underlying how the genetic variation in this locus was able to influence breast cancer susceptibility and further the treatment for this disease.

Introduction

Breast cancer is the most common cancer type reported in women, and certain individuals have been shown to have a genetic predisposition to its development (1). To elucidate the genetic contribution to this disease, numerous genome-wide association studies (GWASs) have been performed, and based on these studies, certain susceptibility loci have been reported. Among these genetic markers, rs1011970 in chromosome 9p21 has been reported to be associated with breast cancer in multiple GWASs (2-4). That is, the carrier of the risk allele at rs1011970 presents with a markedly higher chance (10-20%) to develop breast cancer than carriers of another allele (2-4). However, it is important to note that this mutation may not be the actual causal single nucleotide polymorphism (SNP) for breast cancer. Indeed, usually only ~500,000 SNPs are utilized to represent the variation of the whole genome out of a total of ~80 million SNPs (5). Therefore, it is possible that the actual causal SNP for breast cancer may be an SNP or SNPs that exist in strong linkage disequilibrium (LD) with rs1011970, which has been frequently reported in recent functional genomics studies based on GWAS results (6-8). Moreover, as this SNP is located within the intron of cyclin-dependent kinase inhibitor 2B (*CDKN2B*) antisense RNA 1 (*CDKN2B-AS1*) and the protein-coding gene closest to this SNP is *CDKN2B*, it may be hypothesized that this SNP could be associated with breast cancer through the function of these two genes (2-4). However, to the best of our knowledge, the study of this issue has not previously been reported. All these factors hinder our understanding of the association between this locus and breast cancer susceptibility.

Therefore, the present study used functional genomics approaches to identify the identity of the actual causal SNP at this locus and to elucidate the underlying mechanism associated with this SNP in breast cancer. Through population genetics analysis, rs77283072 was demonstrated to be in nearly complete LD with rs1011970. Therefore, its function and role in breast cancer were also evaluated.

Correspondence to: Dr Chang Sun or Ms. Qiao-Na Shi, College of Life Sciences, Shaanxi Normal University, 620 West Chang'an Road, Xi'an, Shaanxi 710119, P.R. China
E-mail: sunchang@snnu.edu.cn
E-mail: 2039562078@qq.com

*Contributed equally

Key words: breast cancer, susceptibility, rs1011970, rs77283072, *CDKN2A*

Materials and methods

1000 Genomes Project (1KG) data analysis. The nucleotide sequence for the 200 kb surrounding the region of rs1011970 was downloaded from the 1KG project (<http://www.internationalgenome.org/>) for three representative populations,

namely, the Utah Residents with European Ancestry (CEU), Han Chinese in Beijing (CHB) and Yoruba in Ibadan (YRI) populations. The LD pattern was assessed using the Genome Variation Server 150 (<http://gvs.gs.washington.edu/GVS150/>).

Dual-luciferase assay. DNA was purified from the MCF-7 cell line using a standard phenol-chloroform approach. The region proximal to rs1011970 (~1.5 kb) was determined using PCR with Phusion® High-Fidelity DNA Polymerase (Thermo Fisher Scientific, Inc.) and the primer pair 5'-TATCTATTCAGCAAAGCCCCACTC-3' and 5'-ATTAAGGGCTGCCAAGTCACAA-3' (restriction enzyme cutting sites not shown) with the following thermocycling conditions: 98°C for 30 sec; followed by 40 cycles of 98°C for 10 sec, 62°C for 30 sec and 72°C for 45 sec, and finally 72°C for 5 min. The PCR product was separated in 1.5% agarose gel and visualized using SYBR gold (Beijing Solarbio Science & Technology Co., Ltd.). After digestion with *MluI* and *XhoI* (New England BioLabs, Inc.), PCR products were ligated with a luciferase reporter, pGL3-promoter vector (Promega Corporation). After Sanger sequencing with primers 5'-AAACAAAACGAAACAAAA CAACT-3' and 5'-GCGGAGTTAGGGGCGGGATGG-3' (Tsingke Biological Technology), the plasmid containing another allele (T and A for rs1011970 and rs77283072, respectively) was constructed using a Q5 Site-directed Mutagenesis Kit (New England BioLabs, Inc.; primer sequences are presented in Table SI). Prior to transfection, all plasmids were re-sequenced to verify their sequences and the haplotype orientation.

The human breast cancer cell line, MCF-7, was purchased from Conservation Genetics CAS Kunming Cell Bank (<http://www.kmcellbank.com/>) and cultured in HyClone® Dulbecco's modified Eagle's medium, high glucose (Cytiva) with 10% fetal bovine serum (Biological Industries) in 5% CO₂ at 37°C. The constructed plasmids (475 ng) were transfected by incubation with Lipofectamine™ 2000 (Thermo Fisher Scientific, Inc.) for 5 min at 37°C. Following transfection, cells were cultured for an additional 36 h at 37°C, washed with phosphate-buffered saline (Beijing Solarbio Science & Technology Co., Ltd.) and lysed. The level of luciferase expression was quantified using a Dual-Luciferase Reporter Assay System (Promega Corporation) and normalized using the read of the pRL-TK plasmid (25 ng; Promega Corporation). Six independent repeats were performed for each transfection.

Chromosome conformation capture (3C). Spatial contacts between the enhancer and promoter of nearby genes were evaluated using 3C and quantitative PCR (qPCR). Briefly, MCF-7 cells (~1x10⁸) were cross-linked using 1% formaldehyde (Beijing Solarbio Science & Technology Co., Ltd.) and lysed using lysis buffer (Solarbio) on ice for 10 min, and their chromatin was digested using *EcoRI* at 37°C overnight. After ligation, the DNA was purified using a standard phenol-chloroform method (9). The bacterial artificial chromosome RP11-478M20 containing the genome segment chr9: 21947303-22110179 (Genome Reference Consortium Human Build 37) was cultured overnight at 37°C, isolated, digested, ligated as a control and quantified using qPCR. qPCR was performed using iQ™ SYBR® Green (Bio-Rad Laboratories, Inc.) with following thermocycling conditions: 96°C for

10 min; followed by 40 cycles of 96°C for 10 sec and 60°C for 30 sec. The enrichment for chromatin was evaluated using the 2^{-ΔΔC_q} approach (10). The primer sequences are presented in Table SII. Three repeat experiments were performed for each unidirectional anchor primer.

RNA-sequencing (RNA-seq) analysis. The RNA-seq data for lymphoblastoid cell lines (LCL) from a previous study (11) were obtained from the Sequence Read Archive database (<https://www.ncbi.nlm.nih.gov/sra/>) and aligned with the *CDKN2A* mRNA sequence using bowtie2 2.4.4 (12). *CDKN2A* expression was calculated using eXpress (13) with default parameters and reported as fragments per kilo base of transcript per million mapped fragments. The genotype for LCL was obtained from the 1KG database and linear regression was performed between genotype and *CDKN2A* expression using SPSS 20.0 (IBM Corp.). Moreover, the association between rs77283072 and other genes were searched in GTEx database (<https://gtexportal.org>).

Electrophoretic mobility-shift assay (EMSA). Nuclear extracts were isolated from MCF-7 cells using a Nuclear and Cytoplasmic Protein Extraction kit (Beyotime Institute of Biotechnology) and centrifuged at 14,000 x g for 10 min at 4°C. The concentration of nuclear protein was determined using an Enhanced BCA Protein Assay Kit (Beyotime Institute of Biotechnology). The probes for both alleles of rs77283072, which were synthesized by Sangon Biotech Co., Ltd., and the sequences are presented in Table SIII. The probes were labeled with biotin using an EMSA Probe Biotin Labeling Kit (Beyotime Institute of Biotechnology). Biotin-labeled probes (10 fmol) and nuclear extracts (5 μg) were incubated in EMSA binding buffer at room temperature for 20 min. The probe-protein complexes were separated by electrophoresis using a 4.9% non-denatured polyacrylamide gel and then transferred to nylon membranes (Beyotime Institute of Biotechnology). For each allele, probes labeled with biotin alone, and probe-protein complex incubated with competitor oligonucleotides (non-labeled probes) were also included as controls. The membranes were incubated with streptavidin-horseradish peroxidase conjugate (Beyotime Institute of Biotechnology) at room temperature for 5 min and then assessed using an ECL chemiluminescence kit (MilliporeSigma).

Chromatin immunoprecipitation (ChIP) assay. The histone modification surrounding rs77283072 was searched in the ENCODE Portal database (<https://www.encodeproject.org/>) using its location. The online programs Match (<http://www.gene-regulation.com/cgi-bin/pub/programs/match/bin/match.cgi>) and JASPAR (<http://jaspar.genereg.net/>) were used to predict potential transcription factors (TFs) by inputting the surrounding sequence of rs77283072. ChIP was performed using an EZ ChIP Kit (MilliporeSigma). Briefly, MCF-7 cells (~1x10⁷ cells) were cross-linked using formaldehyde at 37°C for 10 min. After washing, the cells were scraped, lysed using lysis buffer (MilliporeSigma) on ice for 10 min, sonicated on ice for 20 cycles (10 sec each) into small fragments (400-800 bp) and pre-cleared with 60 μl protein A beads. The protein-chromatin complex (1 ml) was immunoprecipitated using 2 μg mouse antibody for predicted TFs or normal mouse

IgG (Santa Cruz Biotechnology, Inc.) as a control at 4°C overnight. The antibodies for the following TFs were utilized: REL proto-oncogene (cat. no. sc-373713X), ETS transcription factor ELK1 (cat. no. sc-65986), POU class 2 homeobox 1 (cat. no. sc-8024) or paired box 6 (cat. no. sc-53106; Santa Cruz Biotechnology Inc.). After washing with low salt, high salt, LiCl and TE buffer (MilliporeSigma), the captured protein-chromatin complex was dissolved using elution buffer (MilliporeSigma) and the cross-link was broken by adding 20 μ l 5M NaCl and heating at 65°C for 4 h. Protein was removed by digestion using proteinase K (Roche Diagnostics) at 45°C for 1 h and the DNA was purified using the column supplied with the EZ ChIP Kit. Finally, qPCR was performed to evaluate the enrichment of the DNA obtained using iQTM SYBR[®] Green (Bio-Rad Laboratories, Inc.) and the primers as follows: 5'-TCATGTGGCAGTGGCAAGAGTAAAA-3' and 5'-AGGGTGAGGTAAGTGAATCCCCGAG-3'. This primer pair was designed based on the genome segment surrounding rs77283072. The thermocycling conditions were as follows: 96°C for 10 min; followed by 40 cycles of 96°C for 10 sec and 60°C for 30 sec. Since a standard curve approach and multiple calibrations and controls were used in qPCR, a reference gene is not necessary for this experiment (14). For each ChIP assay, a positive control segment (one genome region that was known to bind TF) (15-18) was included and ChIP-qPCR was performed using the primers in Table SIV.

ChIP-seq data were obtained from the Sequence Read Archive database and aligned with human genome sequence using bowtie2 2.4.4 (12). The enrichment for TFs was evaluated by software MACS 1.4.4 (Model-based analysis of ChIP-seq) (19).

Statistical analysis. Independent Student's t-tests were used to compare the luciferase activities and ChIP results. Analysis of variance (ANOVA) and Bonferroni's post hoc test were used to evaluate the 3C enrichment. Linear regression with additive genetic model was used to evaluate the association between genotype and gene expression. All statistical analyses were performed using SPSS 20.0 (IBM Corp.). $P < 0.05$ was considered to indicate a statistically significant difference.

Results

LD pattern surrounding rs1011970. Within the 200-kb region surrounding rs1011970, genetic variations were identified in the CEU (n=792), CHB (n=793) and YRI (n=1,324) populations. Among these, only one non-coding SNP located 1.3 kb upstream, rs77283072, was in almost complete LD with rs1011970 ($r^2=1.000$, 0.951 and 1.000 for CEU, CHB and YRI, respectively; Fig. S1) and was therefore expected to present a similar signal to that of rs1011970 in GWAS. All other SNPs exhibited relatively low LD with rs1011970 (all $r^2 < 0.64$). Therefore, it was possible to hypothesize that these two SNPs were likely to be the causal SNPs in breast cancer.

Function of rs1011970 and rs77283072. To elucidate the function of these two SNPs, plasmids with different alleles of rs1011970 and rs77283072 were generated (Fig S2), and transfection and luciferase assessment were performed. As presented in Fig. 1, the rs1011970 alleles did not demonstrate




Figure 1. Relative enhancer activity for rs1011970 and rs77283072 alleles in MCF-7 cells. Each line represents one plasmid. The top plasmid is the empty vector (pGL3-promoter). The second plasmid was made using molecular cloning, whereas the lowest two plasmids were constructed using mutagenesis. All data were normalized against that of an empty vector and are presented as the mean \pm standard deviation. * $P < 0.05$.

any significant difference in relative luciferase activity levels ($P=0.988$). However, the luciferase activity levels of the A allele of rs77283072 was ~93.4% higher compared with that of the G allele ($P=0.000068$), which indicated that rs77283072 was the causal SNP in breast cancer.

Regulatory target gene of the enhancer containing rs77283072. As presented in Fig. S3, a search using the ENCODE Portal demonstrated that there were H3K4m1 and H3K27ac histone modifications close to rs77283072. As these two types of histone modification were previously reported to be the markers for active enhancers (20), it was possible to hypothesize that this SNP might have the ability to alter enhancer activity. Meanwhile, there were also other kinds of histone modifications with unknown function, such as H3K36m3 and H4K20m1 (Fig. S3). Although rs77283072 is located within the intron region of *CDKN2B-AS1*, the actual regulatory target of this enhancer remains unknown. To identify the potential target, 3C-qPCR was used to assess the interaction between this enhancer and proximal gene promoters. The anchor promoter was intended to bind the enhancer region, whereas the target primers were designed to bind with the promoter of *CDKN2A* divergent transcript (*CDKN2A-DT*), *CDKN2A*, *CDKN2B-AS1* and *CDKN2B*, and four random genome regions. The amounts of 3C products were used to represent the interaction frequency between the enhancer and target gene promoter, and were compared using ANOVA. As presented in Fig. 2, no increases in interaction were demonstrated in the promoters of *CDKN2A-DT*, *CDKN2B-AS1* and *CDKN2B*. However, if we compared the ligation frequency between *CDKN2A* promoter and other 7 segments involved in the assay, a significant increase could be observed at the *CDKN2A* promoter (~86.0 kb between the *CDKN2A* promoter and the enhancer; $P=0.0038$), which indicated that *CDKN2A* was the regulatory target of this enhancer.

Expression quantitative trait locus (eQTL) analysis. If rs77283072 was indeed capable of regulating *CDKN2A* expression, this SNP would be an eQTL for this gene. To evaluate this hypothesis, RNA-seq data for a widely used model, LCL, was downloaded and *CDKN2A* mRNA expression levels were




Figure 2. Distribution of relative ligation efficiency between the enhancer containing rs77283072 and multiple genome segments in chromosome 9. Each point on the x-axis represents one restriction fragment in chromosome 9. The functional element within the restrictive fragment is stated in parentheses. The y-axis represents the relative ligation efficiency. CDKN2A, cyclin-dependent kinase inhibitor 2A. *P<0.05 when comparing this segment with other ones in the assay.

assessed. Linear regression was performed to evaluate the association between genotype and gene expression. As presented in Fig. 3, *CDKN2A* mRNA expression levels were demonstrated to be significantly associated with the rs77283072 genotype ($r=0.188$; $P=0.021$). The A allele of rs77283072 was associated with a higher mRNA expression level of *CDKN2A*, a finding that was consistent with the results of the luciferase assay.

Differences in the TF binding affinity between the rs77283072 alleles. Considering the function and location of rs77283072, it was hypothesized that this SNP could have the ability to alter the binding affinity of TFs. To evaluate this, EMSA was performed. As presented in Fig. 4, a marked difference was demonstrated in the binding affinity between the rs77283072 alleles. The interaction of probe and nuclear proteins was abolished by competitor oligonucleotides, which indicated that the binding was specific. Furthermore, the more highly expressed allele of rs77283072, the A allele, demonstrated a markedly lower affinity with nuclear proteins, which suggested that the protein interacting with the enhancer containing rs77283072 exerted a negative regulatory effect on gene expression.

These results indicated that rs77283072 may have been located within the binding sites of the REL proto-oncogene, ETS transcription factor ELK1, POU class 2 homeobox 1 or paired box 6 TFs. To identify the actual TF, ChIP was performed. For each antibody, a positive control segment was included and significant enrichment was shown, as presented in Fig. S4, which demonstrated that the ChIP assay could be utilized to identify the TFs surrounding rs77283072. As presented in Fig. S5, none of the antibodies demonstrated significant enrichment of the chromatin surrounding rs77283072, which indicated that none of the proposed TFs could, in fact, bind this region. Multiple ChIP-seq data was also analyzed for TFs. However, no significant enrichment was identified for the rs77283072 surrounding region (all




Figure 3. Association between rs77283072 genotype and *CDKN2A* mRNA expression levels in the Yoruba in Ibadan population from the 1000 Genomes Project dataset. The x-axis indicates the different genotypes. CDKN2A, cyclin-dependent kinase inhibitor 2A.




Figure 4. Different binding affinities between rs77283072 alleles and NE of MCF-7 cells. The top line indicates the different alleles. The arrow indicates the position of the protein-probe complex. NE, nuclear extract.

$P>0.05$; data not shown). Therefore, the identity of the TF that interacted with this enhancer remained unclear.

Discussion

In the present study, the LD pattern was utilized to search for potential causal SNPs for breast cancer. Through a functional genomics approach, both the actual causal SNP and the underlying mechanism were identified. The results of the present study indicated that it was not rs1011970 but rs77283072 that could influence individual breast cancer risk by the regulation of *CDKN2A* expression levels. The present study demonstrated the connection between the genetic variation in this locus and breast cancer susceptibility.

Owing to the relatively short distance between this locus and *CDKN2B*, it has previously been proposed that the SNPs in this locus are associated with breast cancer through regulation of *CDKN2B* expression (3). Moreover, in the GTEx database, rs77283072 was demonstrated to be significantly associated with *CDKN2B* expression levels in whole blood ($P=1.1 \times 10^{-10}$). However, the G allele of rs77283072 was the high-expression allele according to the GTEx data, which was in contrast to the results of the luciferase assay in the present study. Moreover, no interaction was demonstrated between the enhancer and *CDKN2B* promoter. Taken together, these findings indicated that *CDKN2B* was not likely to be involved in the association between this locus and breast cancer susceptibility.

However, the 3C results from the present study clearly demonstrated that an interaction did occur between this enhancer and the *CDKN2A* promoter. *CDKN2A* is an important tumor suppressor gene, which mainly encodes two proteins through alternative splicing, p16^{INK4A} and p14ARF, both of which have been reported to inhibit the cell cycle (21). p16^{INK4A} is able to prevent the activity of cyclin-dependent kinase 4/6 and retinoblastoma protein (22,23). However, p14ARF has been reported to stabilize the tumor suppressor protein p53 through interaction with murine double minute 2 (24,25). It has been proposed that the inactivation of *CDKN2A* either by mutation or through DNA methylation occurs in ~20% of patients with breast cancer (26). Therefore, the observation that rs77283072 was able to influence the risk of breast cancer by regulating *CDKN2A* mRNA expression levels was not unexpected. Considering the widespread and universal functions of the proteins p16^{INK4A} and p14ARF, rs77283072 might also contribute to the onset of carcinogenesis in other tissues. Moreover, rs77283072 has been reported to be significantly associated with prostate cancer, according to one GWAS ($P=6.4 \times 10^{-7}$) (27). Furthermore, the association between rs1011970 and multiple cancer types (4) could also be attributed to the function of rs77283072.

It would have been ideal to identify the potential TFs which interacted with rs77283072 in the present study. ChIP assays were performed for all predictions using common bioinformatics approaches but failed to identify the TF binding rs77283072. Multiple ChIP-sequencing datasets were also used and the reads were aligned with the human genome using bowtie2 (10), and the enrichment was analyzed using software MACS (19). However, no significant peaks for any TFs in the rs77283072 surrounding region were identified (data not shown). As there are hundreds of TFs within the human cell, it is difficult to directly perform ChIP assays without bioinformatics work and this requires further investigation.

In the luciferase experiment, the relative enhancer activity of the A/T combination for rs77283072/rs1011970 locus was

not investigated, which constitutes a potential limit for the study. However, since SNPs usually executes their role on gene expression relatively independently, this might not alter the conclusion that rs1011970 does not have the ability to alter *CDKN2A* expression and further influence breast cancer risk.

Acknowledgements

Not applicable.

Funding

The present study was supported by the National Natural Science Foundation of China (grant no. 31370129) and the Fundamental Research Funds for the Central Universities (grant no. GK202001004).

Availability of data and materials

The datasets used and/or analyzed during the current study are available at https://www.jianguoyun.com/p/DYEJH4wQ_cv3BRizpOkeIAA and from the corresponding author on reasonable request.

Authors' contributions

CS conceived and designed the study, and wrote the manuscript. GHH, SDL, XQS, YC, LS and QNS performed the experiments. GHH analyzed the data. GHH and CS confirm the authenticity of all the raw data. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 71: 209-249, 2021.
2. Michailidou K, Beesley J, Lindstrom S, Canisius S, Dennis J, Lush MJ, Maranian MJ, Bolla MK, Wang Q and Shah M: Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. *Nat Genet* 47: 373-380, 2015.
3. Turnbull C, Ahmed S, Morrison J, Pernet D, Renwick A, Maranian M, Seal S, Ghoussaini M, Hines S, Healey CS, *et al*: Genome-wide association study identifies five new breast cancer susceptibility loci. *Nat Genet* 42: 504-507, 2010.
4. Fehrer G, Kraft P, Pharoah PD, Eeles RA, Chatterjee N, Schumacher FR, Schildkraut JM, Lindström S, Brennan P, Bickeböller H, *et al*: Cross-cancer genome-wide analysis of lung, ovary, breast, prostate, and colorectal cancer reveals novel pleiotropic associations. *Cancer Res* 76: 5103-5114, 2016.

5. The 1000 Genomes Project Consortium: A global reference for human genetic variation. *Nature* 526: 68-74, 2015.
6. Li YK, Zhang XX, Yang Y, Gao J, Shi Q, Liu SD, Fu WP and Sun C: Convergent evidence supports TH2LCRR as a novel asthma susceptibility gene. *Am J Respir Cell Mol Biol* 66: 283-292, 2022.
7. Li X, Xu X, Fang J, Wang L, Mu Y, Zhang P, Yao Z, Ma Z and Liu Z: Rs2853677 modulates snail1 binding to the TERT enhancer and affects lung adenocarcinoma susceptibility. *Oncotarget* 7: 37825-37838, 2016.
8. Almeida R, Ricano-Ponce I, Kumar V, Deelen P, Szperl A, Trynka G, Gutierrez-Achury J, Kanterakis A, Westra HJ, Franke L, *et al*: Fine mapping of the celiac disease-associated LPP locus reveals a potential functional variant. *Hum Mol Genet* 23: 2481-2489, 2014.
9. Hagege H, Klous P, Braem C, Splinter E, Dekker J, Cathala G, de Laat W and Forné T: Quantitative analysis of chromosome conformation capture assays (3C-qPCR). *Nat Protoc* 2: 1722-1733, 2007.
10. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods* 25: 402-408, 2001.
11. Pickrell JK, Marioni JC, Pai AA, Degner JF, Engelhardt BE, Nkadori E, Veyrieras JB, Stephens M, Gilad Y and Pritchard JK: Understanding mechanisms underlying human gene expression variation with RNA sequencing. *Nature* 464: 768-772, 2010.
12. Langmead B and Salzberg SL: Fast gapped-read alignment with Bowtie 2. *Nat Methods* 9: 357-359, 2012.
13. Roberts A and Pachter L: Streaming fragment assignment for real-time analysis of sequencing experiments. *Nat Methods* 10: 71-73, 2013.
14. Nie L, Vazquez AE and Yamoah EN: Identification of transcription factor-DNA interactions using chromatin immunoprecipitation assays. *Methods Mol Biol* 493: 311-321, 2009.
15. Li XX, Peng T, Gao J, Feng JG, Wu DD, Yang T, Zhong L, Fu WP and Sun C: Allele-specific expression identified rs2509956 as a novel long-distance cis-regulatory SNP for SCGB1A1, an important gene for multiple pulmonary diseases. *Am J Physiol Lung Cell Mol Physiol* 317: L456-L463, 2019.
16. Zhang X, Gamble MJ, Stadler S, Cherrington BD, Causey CP, Thompson PR, Roberson MS, Kraus WL and Coonrod SA: Genome-wide analysis reveals PADI4 cooperates with Elk-1 to activate c-Fos expression in breast cancer cells. *PLoS Genet* 7: e1002112, 2011.
17. Sun C, Southard C, Witonsky DB, Kittler R and Di Rienzo A: Allele-specific down-regulation of RPTOR expression induced by retinoids contributes to climate adaptations. *PLoS Genet* 6: e1001178, 2010.
18. Shi Q, Yao XY, Wang HY, Li YJ, Zhang XX and Sun C: Breast cancer-associated SNP rs72755295 is a cis-regulatory variation for human EXO1. *Genet Mol Biol* 45: e20210420, 2022.
19. Feng J, Liu T, Qin B, Zhang Y and Liu XS: Identifying ChIP-seq enrichment using MACS. *Nat Protoc* 7: 1728-1740, 2012.
20. Calo E and Wysocka J: Modification of enhancer chromatin: What, how, and why? *Mol Cell* 49: 825-837, 2013.
21. Serra S and Chetty R: p16. *J Clin Pathol* 71: 853-858, 2018.
22. Liggett WH Jr and Sidransky D: Role of the p16 tumor suppressor gene in cancer. *J Clin Oncol* 16: 1197-1206, 1998.
23. Serrano M: The tumor suppressor protein p16INK4a. *Exp Cell Res* 237: 7-13, 1997.
24. Zhang Y, Xiong Y and Yarbrough WG: ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. *Cell* 92: 725-734, 1998.
25. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, *et al*: The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. *Cell* 92: 713-723, 1998.
26. Li J, Poi MJ and Tsai MD: Regulatory mechanisms of tumor suppressor P16(INK4A) and their relevance to cancer. *Biochemistry* 50: 5566-5582, 2011.
27. Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, *et al*: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. *Nat Genet* 50: 928-936, 2018.